We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

176 hedge funds and large institutions have $2.44B invested in Celldex Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 55 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $61.1M | Put options by funds: $35.8M

24% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 55

2.74% more ownership

Funds ownership: 105.59% → 108.33% (+2.7%)

3% less funds holding

Funds holding: 182 → 176 (-6)

5% less capital invested

Capital invested by funds: $2.58B → $2.44B (-$135M)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
176
Holders Change
-6
Holders Change %
-3.3%
% of All Funds
2.53%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
22
Increased
68
Reduced
55
Closed
28
Calls
$61.1M
Puts
$35.8M
Net Calls
+$25.3M
Net Calls Change
+$39M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$66.1M
2
WP
Woodline Partners
California
+$60.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$44.5M
4
Goldman Sachs
Goldman Sachs
New York
+$36.6M
5
LGM
Logos Global Management
California
+$34.3M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$68.8M
2
Marshall Wace
Marshall Wace
United Kingdom
-$42M
3
SI
Sofinnova Investments
California
-$20.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
5
PCH
Polar Capital Holdings
United Kingdom
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Public Employees Retirement Association of Colorado
126
Public Employees Retirement Association of Colorado
Colorado
$265K – – –
Royal Bank of Canada
127
Royal Bank of Canada
Ontario, Canada
$263K +$42.9K +1,127 +17%
OMC
128
Overbrook Management Corp
New York
$232K – – –
Los Angeles Capital Management
129
Los Angeles Capital Management
California
$229K -$24.1K -633 -9%
AIP
130
Ameritas Investment Partners
Nebraska
$222K +$13.2K +346 +6%
PIA
131
Panoramic Investment Advisors
Colorado
$221K +$248K +6,500 New
KeyBank National Association
132
KeyBank National Association
Ohio
$216K +$242K +6,356 New
Canada Life
133
Canada Life
Manitoba, Canada
$215K -$277K -7,279 -53%
ACM
134
ADAR1 Capital Management
Texas
$170K +$179K +4,697 +1,550%
Acadian Asset Management
135
Acadian Asset Management
Massachusetts
$156K +$175K +4,591 New
VEA
136
Virtus ETF Advisers
New York
$86K +$1.68K +44 +2%
AB
137
Amalgamated Bank
New York
$74K – – –
KBC Group
138
KBC Group
Belgium
$71K +$18.9K +495 +31%
Russell Investments Group
139
Russell Investments Group
United Kingdom
$60.1K -$86.9K -2,280 -56%
A
140
AlphaQuest
New York
$53.8K -$221K -5,801 -79%
FDCDDQ
141
Federation des caisses Desjardins du Quebec
Quebec, Canada
$52.5K +$381 +10 +0.7%
PAS
142
Point72 Asia (Singapore)
Singapore
$41.1K -$32.1K -843 -41%
Nisa Investment Advisors
143
Nisa Investment Advisors
Missouri
$23.2K +$1.33K +35 +5%
US Bancorp
144
US Bancorp
Minnesota
$23.2K +$1.72K +45 +7%
CIBC Private Wealth Group
145
CIBC Private Wealth Group
Georgia
$17K – – –
Osaic Holdings
146
Osaic Holdings
Arizona
$16.7K -$7.54K -198 -29%
EWA
147
EverSource Wealth Advisors
Alabama
$13.8K – – –
National Bank of Canada
148
National Bank of Canada
Quebec, Canada
$12.9K – – –
CSC
149
Caldwell Sutter Capital
California
$11.9K – – –
FHA
150
First Horizon Advisors
Tennessee
$11.3K – – –
4 5
6
7 8

CLDX Hedge Fund Activity: Q3 2024 in Review

176 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2024, worth a combined $2.44B — down 5.2% from $2.58B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CLDX and 22 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 68 added.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $66.1M. The largest seller was Fidelity Investments, cutting an estimated $68.8M.

  • 176 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2024, down from 182 in Q2 2024.
  • Funds reported $2.44B of Celldex Therapeutics stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 22 funds opened new Celldex Therapeutics positions in Q3 2024 and 28 closed out, a net change of -6 holders.
  • The largest Celldex Therapeutics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $66.1M added.
  • The largest Celldex Therapeutics seller in Q3 2024 was Fidelity Investments, an estimated $68.8M sold.

Based on aggregated 13F filings for Q3 2024.